Results (
Thai) 1:
[Copy]Copied!
Secondary objectives:• To determine if PI-based HAART is superior to NRTI-based HAART when used for the purpose of preventing antepartum and intrapartum MTCT by comparing the percentage of women in each randomization arm with HIV-1 RNA < 50 copies/mL and < 1000 copies/mL at delivery and throughout the breastfeeding period.• To determine if laboratory and clinical toxicities among pregnant/postpartum women and their infants, and adherence to treatment regimen among women, differ by randomized treatment arm through 12 months postpartum.• To compare long-term infant toxicities and neurodevelopment with infants in the Mashi Study.• To determine the extent of correlation between breast milk HIV-1 RNA and DNA and plasma HIV-1 RNA among women receiving HAART, to describe differences in correlation by randomization arm and time on HAART, and to explore the association of breast milk HIV-1 RNA and DNA and plasma HIV-1 RNA with overall and breastfeeding MTCT.• To quantify the viral load threshold for MTCT while receiving HAART in the antepartum, intrapartum, and breastfeeding periods by describing plasma and breast milk HIV-1 RNA values closest to HIV transmission among transmitting mother-infant pairs.• To determine if HIV resistance mutations differ by randomization arm, and whether resistance mutations and low antiretroviral concentrations in plasma (mothers and infants) and breast milk (mothers) are associated with MTCT, by evaluating transmitting mother-infant pairs and a matched group of non- transmitting pairs.• To determine if HAART started in pregnancy is associated with prematurity or low birth weight or developmental delay or morbidity by describing rates of prematurity and low birth weight infant and growth parameters and morbidity by randomization arm, and in comparison with an historical group of infants born to women at the same sites who received ZDV alone during pregnancy in the Mashi Study.
Being translated, please wait..